Siddharth Bothra

Similar documents
Hardick Bora

Sanjay Jain Pavas Pethia

Niket Shah

Jinesh Gandhi Chirag Jain

CMP: INR350 TP: INR375 Downgrade to Neutral

Sohail Halai Alpesh Mehta

Hardick Bora 4QCY12 Results Update Sector: Healthcare Sanofi India CMP: INR2,307 TP: INR2,015 Neutral

Titan Industries. CMP: INR222 TP: INR220 Neutral

Jinesh Gandhi Chirag Jain

Pidilite Industries. CMP: INR164 TP: INR186 Buy

Idea Cellular. CMP: INR159 TP: INR200 Buy

Sandipan Pal QFY13 Results Update Sector: Real Estate Unitech CMP: INR29 TP: INR44 Buy

Sanofi India. CMP: INR2,200 TP: INR1,848 Neutral

Jinesh Gandhi Sandipan Pal

Jubilant Foodworks. CMP: INR1,189 TP: INR1,0541,054 Neutral

NTPC CMP: INR169 TP: INR191 Buy

Asian Paints. CMP: INR2,722 TP: INR3,161 Buy

Canara Bank. CMP: INR419 TP: INR525 Buy

Godrej Consumer Products

IndusInd Bank. CMP: INR345 TP: INR419 Buy

Cross service charges at INR m/quarter

Idea Cellular. CMP: INR81 TP: INR Under Review

BGR Energy. CMP: INR282 TP: INR253 Neutral

Urban demand revives; Akzo gaining market share

Hardick Bora QFY13 Results Update Sector: Healthcare Lupin CMP: INR725 TP: INR851 Buy

BGR Energy. CMP: INR266 TP: INR230 Neutral

Stress test: Weak capital servicing ratios to drive pricing discipline

Larsen & Toubro. CMP: INR1,160 TP: INR1,417 Buy

Reliance Infrastructure CMP: INR528

Amara Raja Batteries. CMP: INR517 TP: INR560 Buy

Jaypee Infratech. CMP: INR33 TP: INR45 Buy

Market share recovery, price hike, content leverage to drive growth

Strides Arcolab. CMP: INR717 TP: INR829 Buy

Punjab National Bank. CMP: INR716 TP: INR950 Buy

Unitech. CMP: INR20 TP: INR30 Buy

Hardick Bora 4QFY13 Results Update Sector: Healthcare Dr Reddy's Laboratories CMP: INR2,026 TP: INR2,375 Buy

Alpesh Mehta Sohail Halai

BGR Energy. CMP: INR284 TP: INR296 Neutral

Kotak Mahindra Bank. CMP: INR495 TP: INR429 Neutral

Castrol India. CMP: INR407 TP: INR474 (+16%) Neutral

Punjab National Bank. CMP:INR1,103 TP:INR1,500 Buy

Just Dial. CMP: INR1,129 TP: INR1,475 Buy

Petronet LNG. CMP: INR146 TP: INR205 Buy

Coal India CMP: INR348 TP: INR408 Buy

Kotak Mahindra Bank. CMP: INR626 TP: INR500 Neutral

CMP: INR121 TP: INR193 Buy

Godrej Properties. CMP: INR368 TP: INR420 Neutral

Shoppers Stop. CMP: INR339 TP: INR355 Neutral

Jaiprakash Associates

CPCB-2: Important long-term driver

M&M Financial Services

Gautam Duggad Sreekanth P V S

IDBI Bank. CMP: INR106 TP: INR121 Neutral

JSW Steel. CMP: INR670 TP: INR391 Sell Merger with JSW Ispat

Jubilant Foodworks. CMP: INR1,051 TP: INR1,054 Neutral

Canara Bank. CMP: INR464 TP: INR645 Buy

Torrent Pharmaceuticals

Hindalco. CMP: INR113 TP: INR151 Buy

Godawari Power & Ispat

Cummins India. CMP: INR430 TP: INR462 Neutral

Larsen & Toubro. CMP: INR1,278 TP: INR1,380 Buy

Axis Bank. CMP: INR1,119 TP: INR1,330 Buy

Maruti Suzuki. CMP: INR1,395 TP: INR1,730 Buy

Axis Bank. CMP: INR1,008 TP: INR1,240 Buy

Dabur India. CMP: INR130 TP: INR135 Neutral

Shree Renuka Sugars. CMP: INR26 TP: INR45 Buy

Godrej Consumer Products

Automobiles. HMSI s expansion could result in short-term pressure on HMCL and BJAUT

Jinesh Gandhi Sandipan Pal

Punjab National Bank. CMP: INR940 TP: INR1,275 Buy

CMP: INR124 TP: INR172 Buy. Benefit of two major motorcycle launches not priced in. Improved industry outlook and recent launch success drive upgrades

Steel Authority of India

Jinesh Gandhi Sandipan Pal

Dabur India. CMP: INR106 TP: INR94 Neutral

Eicher Motors. CMP: INR9,281 TP: INR11,401 Buy

Raymond. Restructuring initiatives bearing fruit; Land bank base case value INR147/share; Reiterate Buy. CMP: INR385 TP: INR462 Buy

CMP: INR415 TP: INR 471 BUY

Hindustan Unilever. CMP:INR324 TP:INR302 Neutral

Monnet Ispat. CMP: INR449 TP: INR518 Neutral

Punjab National Bank. CMP: INR768 TP: INR963 Buy

Cement. Demand to grow 8%, with cost push to be passed on CCI probe to have limited impact

Oberoi Realty. CMP: INR269 TP: INR320 Buy

CMP: INR320 TP: INR164(-49%) Sell Intending to exit UK execution is key!

Godrej Properties. CMP: INR595 TP: INR635 Neutral

BHEL. CMP: INR227 TP: INR233 Neutral

Sun Pharmaceuticals. CMP: INR554 TP: INR614 Neutral

Individual Housing Loans: Rationalization of Risk-Weights and LTV Ratios

Oberoi Realty. CMP: INR264 TP: INR315 Buy

CMP: INR1,044 TP: INR970 (-7%) Neutral Sale of Healthcare business margin accretive

Britannia Industries. CMP: INR546 TP: INR605 Upgrade to Neutral Volume growth bottoms out; Upgrade to Neutral

Pantaloon Retail. CMP: INR177 TP: INR192 Neutral

KPIT Technologies. CMP: INR175 TP: INR170 Downgrade to Neutral

Tata Power. CMP: INR111 TP: INR92 Neutral

To voluntarily stop supplies to US

Tribhovandas Bhimji Zaveri

ITC. CMP: INR201 TP: INR230 Buy

CMP: INR475 TP: INR609 (+28%) Buy

CMP: INR826 TP: INR810 (-2%) Neutral

Oberoi Realty. CMP: INR240 TP: INR297 Buy

Expect capacity-led rerating; maintain Buy

Transcription:

BSE Sensex S&P CNX 19,152 5,797 Bloomberg CSTRL IN Equity Shares (m) 494.6 M.Cap. (INR b)/(usd b) 158/2.9 52-Week Range (INR) 338/223 1,6,12 Rel. Perf. (%) 12/-3/26 Financials & Valuation (INR b) Y/E March 2012E 2013E 2014E Sales 31.2 34.0 37.1 EBITDA 6.2 7.7 8.7 Adj NP 4.5 5.5 6.2 EPS (INR) 9.0 11.1 12.5 EPS Gr. (%) -7 23 12 BV/Sh (INR) 13.1 14.3 15.7 RoE (%) 83.8 71.5 81.1 RoCE (%) 109.1 94.3 109.9 Payout (%) 90.2 89.2 88.8 Valuations P/E (x) 35.3 28.7 25.6 P/BV (x) 24.4 22.3 20.3 EV/EBITDA (x) 24.6 19.5 17.3 Div Yield (%) 2.2 2.7 3.0 28 February 2013 4QCY12 Results Update Sector: Consumer Castrol India CMP: INR319 TP: INR316 Neutral Castrol's (CSTRL) 4QCY12 results are in line, with net sales at INR7.6b, down 1.1% YoY (est of INR8b) and EBITDA at INR1.7b, up 10.7% YoY (est of INR1.7b). EBITDA margin stood at 22.3% (up 238bp YoY and 542bp QoQ), while PAT increased 10% YoY to INR1.2b (in-line). For CY12, revenues were up by 6.1% YoY to INR31.6b, EBITDA was down 6.3% YoY to INR6.2b, while PAT was down 7% YoY to INR4.5b. 4QCY12 witnessed the full impact of successive price hikes taken by CSTRL over CY12 and offset the negative volume pressure from the industrial and auto segments. Auto segment reported flat value growth, while industrial and marine value declined 9%. Non auto segment accounts for ~12% of CSTRL's total sales. During CY12, company's total payout ratio (dividend + dividend tax) stood at 90% from 89% in CY11. Total dividend for CY12 stood at INR7/share (post split impact). Over CY02-11, CSTRL generated FCF of INR27b, with total reinvestment of negative INR3b. Cumulative net capex (capex - depreciation) over the period was a negative INR408m, while cumulative net working capital (net of cash) was a negative INR2.5b. Company paid 87% of its FCF as dividend. We believe this reflects the asset light nature and robustness of its business model. Valuation and view We expect Castrol to post earnings CAGR of 17% and FCF CAGR of 11% over CY12-14. CSTRL enjoys tremendous pricing power, with most of its products commanding 10-25% premium. CSTRL trades at 28.7x /25.6x its CY13/ CY14 EPS. Our DCF based price target for CSTRL is INR316. Though we continue to remain positive on the long-term prospects of CSRTL, given CSTRL's rich valuations we have a Neutral rating. Siddharth Bothra (Siddharth.Bothra@MotilalOswal.com); +91 22 3029 5127 1 Investors are advised to refer through disclosures made at the end of the Research Report.

Segmental Analysis: Drop in non auto segment volumes offsets auto segment gains Automotive sales were flat, while non-automotive segment de-grew 9% YoY. Non Auto segment accounts for ~12% of CSTRL's total sales. Auto EBIT stood at INR1.6b up 22% YoY, while non auto EBIT stood at INR108m down 54% YoY to INR108m. Management attributed the sharp improvement in margins to a combination of premium product mix and better realization, which successfully negated volume pressure across both the automobile and industrial lube vertical. Segmental analysis: Non-Automotive segment still under pressure(inr m) CY11 CY12 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q Revenues Automotive 6,507 6,729 5,652 6,653 6,744 7,515 6,248 6,662 Non-Automotive 1,000 1,171 1,064 1,041 1,073 998 947 947 Total Segment Revenue 7,507 7,900 6,716 7,694 7,817 8,513 7,195 7,609 EBIT Automotive 1,646 1,645 1,042 1,283 1,461 1,499 1,036 1,562 Non-Automotive 266 292 257 233 243 186 149 108 Total 1,912 1,937 1,299 1,516 1,704 1,685 1,185 1,670 Capital Employed Automotive 2,233 1,997 2,445 1,277 2,595 2,122 2,046 1,231 Non-Automotive 1,017 1,138 1,174 1,020 1,164 1,021 1,042 878 Unallocated Net Assets/ Liabilities 3,651 3,179 3,653 3,745 3,513 3,325 4,238 4,382 Total Capital Employed 6,901 6,314 7,272 6,042 7,272 6,468 7,326 6,491 EBIT (%) Automotive 25.3 24.4 18.4 19.3 21.7 19.9 16.6 23.4 Non-Automotive 26.6 24.9 24.2 22.4 22.6 18.6 15.7 11.4 Total 25.5 24.5 19.3 19.7 21.8 19.8 16.5 21.9 Source: Company, MOSL Margin/unit to sustain, though volume growth to be muted Over CY01-11, Castrol's sales volumes have de-grown, not only due to increasing drain interval, but also because it has deliberately vacated the price-sensitive volume-driven market. Castrol depends on technology innovation and path breaking new product launches to drive growth and ability to organically generate growth through internal initiatives is the most sustainable source of growth. We model Castrol's net sales growth over CY12-21 at 9%. Concerns on account of increasing drain intervals are largely unfounded, as Castrol has historically maintained its margin/unit, which we believe it can sustain. We estimate 2.4% CAGR in Castrol's volumes over CY12-14. However, revenue would grow at a CAGR of 9%, driven by 6% CAGR in realizations. We expect EBIT margin to expand from 19.5% in CY11 to 22.2% in CY14 and estimate net profit CAGR at 17% over CY12-14. We have estimated volume growth of 1.5% in CY12 and 2.4% in CY13. Almost ~80% of Castrol's demand in volume terms is from replacement market, while the OEM market accounts for only ~20%. Since the profitability in the OEM 28 February 2013 2

segment is very low, the share of OEM market in operating profit is consequently even lower. Hence, we believe Castrol is unlikely to be much impacted from the current growth slowdown in few automobile segments such as HCV and 2wheelers. Management growth outlook for key segments The management has guided for auto lube volume growth of 2-2.5% over the next 3-5 years. Castrol's auto lube sales break-up: diesel engine oils (mostly CVs) 40%, 2-wheelers 20%, passenger cars 15% and OEM/ Construction/ Brake oil, etc 25%. Its key focus area is the premium personal mobility automobile segment, which is relatively insulated from economic cycles, unlike the freight and OE market. The management expects the 2-wheeler segment to double in volume terms in the next 3-4 years, while the other segments will likely post marginal growth rates. The management expects growth in the industrial segment to be marginally stronger than in the auto segment. Management growth outlook Automobiles: Segment-wise sales break-up Castrol auto volume Company growth outlook over break-up % CY12-15 Diesel Engine Oils 40 Expects very low to marginal growth 2-Wheelers 20 Expects volumes to double in 3-4 years Passenger Cars 15 Expects 1% odd growth OE/ Const/ Others 25 Marginal growth Total 100 2-2.5% growth Source: Conference Call post 3QCY11 results Source: Company, MOSL Automotive industry break-up Castrol's automobile lubricant break-up Almost 75% of the lube demand is derived from CVs and tractors, largely dominated by diesel engines. 2/ 3 wheelers account for another ~13% of the market, while 4 wheelers/ MUVs account for ~5% of the market Source: Industry, MOSL 28 February 2013 3

Valuation and view We believe, CSTRL provides a vehicle to invest in a company with multiple and rare moats, huge free cash flows, high governance standards. CSTRL's primary market is premium personal mobility automobiles, where it is able to leverage its trusted brand, product track record and unique service attributes. Unlike its competitors that have been making low to negligible investments in their brands, Castrol has consistently been investing 6-7% of its sales (INR2.2b in CY11) in brandbuilding. We expect Castrol to post earnings CAGR of 17% and FCF CAGR of 11% over CY12-14. CSTRL enjoys tremendous pricing power, with most of its products commanding 10-25% premium. It has been focusing on improving its product mix through adept market segmentation and innovative products. How effectively Castrol is able to continuously improve its product mix by consistently expanding the premium end of the market and through paradigm breaking new product concepts is a key factor to watch. CSTRL trades at 28.7x /25.6x its CY13/ CY14 EPS. Though we continue to remain positive on the long-term prospects of CSRTL, given CSTRL's rich valuations we have a Neutral rating. 28 February 2013 4

Castrol India: an investment profile Company description Castrol India Limited, a 71% subsidiary of BP, is a leading lubricants player in India, with ~20% market share of the domestic automotive lubricants industry. It manufactures and markets a range of automotive and industrial lubricants. It markets its automotive lubricants under two brands - Castrol and BP. The company enjoys leadership in most of the segments it operates in, including tractor oils, car engine oils, two-wheeler 4- stroke oils, and multi-grade diesel engine oils. Key investment arguments Castrol India, a 71% subsidiary of British Petroleum Group (BP), is a leading lubricants player in India, with ~19% market share in the auto lube bazzar segment. Castrol provides a vehicle to invest in a company with multiple and rare moats, huge free cash flows, high governance standards and reasonable valuations. Its key focus area is the premium personal mobility automobile segment, which is relatively insulated from economic cycles, unlike the freight and OE market. Key investment risk Longer oil drain intervals Volatile raw material prices Aggressive foray by oil PSUs into bazzar trade OEMs introducing own brands Exchange rate volatility Recent developments Re-launch of our leading brand in the motorcycle segment - Castrol Activ, with new Actibond technology. Undertook 3-4% price increase across brands during 4QCY12 to mitigate increasing raw material cost. Valuation and view CSTRL trades at 28.7x /25.6x its CY13/ CY14 EPS. Our DCF based price target for CSTRL is INR316. Though we continue to remain positive on the long-term prospects of CSRTL, given CSTRL's rich valuations we have a Neutral rating. Sector view Competition intensity in the industry remains high, with ~15 players. Nonetheless, CSTRL has been able to sustain its performance given its niche segmentation within the premium personal mobility segment. Lube industry enjoys high ROCE, given low reinvestment requirements. EPS: MOSL forecast v/s Consensus (INR) MOSL Consensus Variation Forecast Forecast (%) CY13 11.1 10.7 4.1 CY14 12.5 11.8 5.9 Target price and recommendation Current Target Upside Reco. Price (INR) Price (INR) (%) 319 316-0.9 Neutral Stock performance (1 year) Shareholding Pattern (%) Dec-12 Sep-12 Dec-11 Promoter 71.0 71.0 71.0 Domestic Inst 6.2 6.5 7.2 Foreign 8.1 8.1 7.4 Others 14.6 14.4 14.4 28 February 2013 5

Financials and Valuation 28 February 2013 6

N O T E S 28 February 2013 7

Disclosures This report is for personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred as MOSt) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOSt or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOSt or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOSt or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. While we would endeavour to update the information herein on reasonable basis, MOSt and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOSt and/or its affiliates from doing so. MOSt or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. This report is intended for distribution to institutional investors. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. MOSt and/or its affiliates and/or employees may have interests/positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. Disclosure of Interest Statement Castrol India 1. Analyst ownership of the stock No 2. Group/Directors ownership of the stock No 3. Broking relationship with company covered No 4. Investment Banking relationship with company covered No Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of MOSt research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues. Regional Disclosures (outside India) This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSt & its group companies to registration or licensing requirements within such jurisdictions. For U.K. This report is intended for distribution only to persons having professional experience in matters relating to investments as described in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (referred to as "investment professionals"). This document must not be acted on or relied on by persons who are not investment professionals. Any investment or investment activity to which this document relates is only available to investment professionals and will be engaged in only with such persons. For U.S. Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account. For Singapore Motilal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act(FAA) read with regulation 17(1)(d) of the Financial Advisors Regulations and is a subsidiary of Motilal Oswal Securities Limited in India. This research is distributed in Singapore by Motilal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time. In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited: Nihar Oza Kadambari Balachandran Email: niharoza.sg@motilaloswal.com Email : kadambari.balachandran@motilaloswal.com Contact: (+65) 68189232 Contact: (+65) 68189233 / 65249115 Office address: 21 (Suite 31), 16 Collyer Quay, Singapore 049318 Motilal Oswal Securities Ltd Motilal Oswal Tower, Level 9, Sayani Road, Prabhadevi, Mumbai 400 025 Phone: +91 22 3982 5500 E-mail: reports@motilaloswal.com